You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

TRIAMCINOLONE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for triamcinolone and what is the scope of patent protection?

Triamcinolone is the generic ingredient in thirty-one branded drugs marketed by Astellas, Delcor Asset Corp, Barr, Impax Labs, Ivax Sub Teva Pharms, Mylan, Purepac Pharm, Roxane, Sandoz, Teva, Watson Labs, Abbvie, Chattem Sanofi, Ivax Pharms, Solvay, Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms Ltd, Micro Labs, Morton Grove, Norvium Bioscience, Padagis Us, Pharmaderm, Pharmafair, Strides Pharma, Taro, Topiderm, Crown Labs, Savage Labs, Pacira Pharms Inc, Apothecon, Amneal, Eugia Pharma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Teva Pharms Usa, Allergan, Harrow Eye, Epic Pharma Llc, Pai Holdings Pharm, Quagen, Wockhardt Bio Ag, Aurobindo Pharma Ltd, Cintex Svcs, Extrovis, Glenmark Speclt, Padagis Israel, Cmp Pharma Inc, Lyne, Sciegen Pharms Inc, Lupin Atlantis, Sanofi Aventis Us, Apotex, Perrigo Pharma Intl, Sun Pharm Inds Inc, Rising, Bausch And Lomb Inc, and Fosun Pharma, and is included in one hundred and sixty-seven NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are fifty-one drug master file entries for triamcinolone.

Drug Prices for TRIAMCINOLONE

See drug prices for TRIAMCINOLONE

Drug Sales Revenue Trends for TRIAMCINOLONE

See drug sales revenues for TRIAMCINOLONE

Recent Clinical Trials for TRIAMCINOLONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
David SheynPhase 2/Phase 3
Ain Shams UniversityPhase 3
Tanta UniversityN/A

See all TRIAMCINOLONE clinical trials

Medical Subject Heading (MeSH) Categories for TRIAMCINOLONE

US Patents and Regulatory Information for TRIAMCINOLONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Padagis Us TRIAMCINOLONE ACETONIDE triamcinolone acetonide OINTMENT;TOPICAL 087385-001 Approved Prior to Jan 1, 1982 AT RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Taro TRIAMCINOLONE ACETONIDE triamcinolone acetonide OINTMENT;TOPICAL 040386-001 Jun 5, 2001 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi NASACORT ALLERGY 24 HOUR triamcinolone acetonide SPRAY, METERED;NASAL 020468-002 Oct 11, 2013 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Morton Grove TRIAMCINOLONE ACETONIDE triamcinolone acetonide OINTMENT;TOPICAL 088090-001 Sep 1, 1983 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fosun Pharma ARISTOCORT triamcinolone diacetate INJECTABLE;INJECTION 011685-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.